Financials in USD. Standardized financial statements.
A compact view of how RVL Pharmaceuticals plc turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Revenue? | $49.72M | $17.50M | $27.76M | $240.03M | $263.70M | $245.75M | $218.46M |
| Revenue Growth? | +184.1% | -37.0% | -88.4% | -9.0% | +7.3% | +12.5% | 0.0% |
| Cost of Revenue? | $9.46M | $3.62M | $3.29M | $111.63M | $140.08M | $125.19M | $125.62M |
| Gross Profit? | $40.27M | $13.88M | $24.47M | $128.40M | $123.62M | $120.56M | $92.84M |
| Gross Margin? | +81.0% | +79.3% | +88.1% | +53.5% | +46.9% | +49.1% | +42.5% |
| Operating Expenses? | $85.94M | $94.39M | $86.21M | $125.35M | $117.94M | $99.64M | $95.02M |
| Operating Income? | -$45.68M | -$80.51M | -$61.74M | $3.94M | -$98.54M | -$52.07M | -$32.05M |
| EBITDA? | -$36.19M | -$73.67M | -$69.72M | -$49.80M | -$664.39M | $62.85M | $21.58M |
| Income Before Tax | -$51.71M | -$82.53M | -$94.80M | -$298.02M | -$118.66M | -$85.64M | -$52.07M |
| Income Tax Expense | -$20,000 | $315,000 | -$5.78M | -$27.12M | -$8.98M | -$40.49M | -$10.25M |
| Net Income? | -$51.69M | -$82.85M | -$89.01M | -$270.90M | -$109.68M | -$45.15M | -$41.82M |
| EPS? | $-0.58 | $-1.23 | $-1.47 | $-5.17 | $-2.42 | $-1.05 | $-0.98 |
| Diluted EPS? | $-0.58 | $-1.23 | $-1.47 | $-5.17 | $-2.42 | $-0.98 | $-0.98 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality